Oxford Biomedica’s next CEO to start in March; Kåre Schultz ready to wrap up Teva tenure early

Frank Mathias

→ Frank Mathias is calling it quits as CEO of German CDMO Rentschler Biopharma, moving instead to UK gene and cell therapy player Oxford Biomedica in March 2023. At that time, he’ll also return to the...

Click to view original post